Regent Peak Wealth Advisors LLC Sells 9,743 Shares of Johnson & Johnson (NYSE:JNJ)

Regent Peak Wealth Advisors LLC reduced its position in Johnson & Johnson (NYSE:JNJ) by 60.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 6,469 shares of the company’s stock after selling 9,743 shares during the quarter. Regent Peak Wealth Advisors LLC’s holdings in Johnson & Johnson were worth $936,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Canandaigua National Trust Co of Florida raised its holdings in shares of Johnson & Johnson by 13.2% in the 4th quarter. Canandaigua National Trust Co of Florida now owns 2,250 shares of the company’s stock worth $325,000 after buying an additional 263 shares in the last quarter. Capital Market Strategies LLC grew its position in Johnson & Johnson by 5.8% in the fourth quarter. Capital Market Strategies LLC now owns 7,723 shares of the company’s stock valued at $1,117,000 after acquiring an additional 425 shares during the period. Pensionfund Sabic raised its stake in Johnson & Johnson by 49.2% during the fourth quarter. Pensionfund Sabic now owns 27,300 shares of the company’s stock worth $3,948,000 after acquiring an additional 9,000 shares in the last quarter. Nordea Investment Management AB boosted its stake in shares of Johnson & Johnson by 13.7% in the 4th quarter. Nordea Investment Management AB now owns 6,424,675 shares of the company’s stock valued at $926,438,000 after purchasing an additional 775,490 shares in the last quarter. Finally, Versant Capital Management Inc grew its holdings in shares of Johnson & Johnson by 27.8% in the 4th quarter. Versant Capital Management Inc now owns 4,678 shares of the company’s stock worth $677,000 after purchasing an additional 1,019 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on JNJ shares. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a report on Wednesday, October 16th. Wolfe Research started coverage on Johnson & Johnson in a report on Friday, November 15th. They issued an “outperform” rating and a $190.00 target price on the stock. Bank of America reaffirmed a “neutral” rating and set a $166.00 price target on shares of Johnson & Johnson in a report on Tuesday, December 10th. Guggenheim boosted their price objective on Johnson & Johnson from $156.00 to $162.00 and gave the stock a “neutral” rating in a research note on Wednesday, November 6th. Finally, Morgan Stanley raised their target price on Johnson & Johnson from $169.00 to $175.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 16th. Seven research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Johnson & Johnson currently has an average rating of “Moderate Buy” and a consensus price target of $174.71.

Insider Transactions at Johnson & Johnson

In other news, Director Mark A. Weinberger acquired 1,000 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, December 12th. The shares were acquired at an average price of $147.22 per share, with a total value of $147,220.00. Following the purchase, the director now directly owns 1,000 shares of the company’s stock, valued at $147,220. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Trading Up 2.0 %

Johnson & Johnson stock traded up $2.91 during trading hours on Tuesday, reaching $146.57. 3,159,256 shares of the company’s stock traded hands, compared to its average volume of 5,719,923. Johnson & Johnson has a fifty-two week low of $142.75 and a fifty-two week high of $168.85. The firm’s 50 day moving average is $151.03 and its 200-day moving average is $156.25. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03. The firm has a market capitalization of $352.89 billion, a price-to-earnings ratio of 21.21, a PEG ratio of 2.52 and a beta of 0.51.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.21 by $0.21. The firm had revenue of $22.47 billion for the quarter, compared to analysts’ expectations of $22.17 billion. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The business’s revenue for the quarter was up 5.2% on a year-over-year basis. During the same period last year, the firm earned $2.66 earnings per share. On average, analysts predict that Johnson & Johnson will post 9.94 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be issued a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a yield of 3.38%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 71.78%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.